These data indicate that SRSF2 and RUNX1 mutations promote an aberrant maturation of erythroid cells in low-risk MDS, and importantly, that the disease phenotype observed in the patient could be reproduced in vitro. Here, SRSF2 is linked to myelodysplastic syndrome.